At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 22 enrolled
Drug / intervention
Olanzapine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa
In Brief
A Phase 4 clinical trial evaluating Olanzapine and Aripiprazole for Eating Disorders. Completed, enrolled 22 participants across 2 sites in 2 countries.
Detailed Summary
This study will compare the effectiveness of two atypical antipsychotic medications, olanzapine and aripiprazole, in treating people with anorexia nervosa.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEating Disorders
CountriesCanada, United States
CollaboratorsNational Institute of Mental Health (NIMH)
Timeline
Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2003
Primary CompletionSep 2006
First PostedMay 2008
TodayJul 2026
First PostedMay 28, 2008
Enrollment StartNov 1, 2003
Primary CompletionSep 1, 2006
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 18.1 years ago
Interventions
Olanzapinedrug
Participants will take olanzapine daily for 12 weeks.
Aripiprazoledrug
Participants will take aripiprazole daily for 12 weeks.